Doximity reported calendar third-quarter revenue of $174.5 million, up 3.6% year on year and ahead of analysts' estimates of $171.1 million. Adjusted earnings per share were $0.36, in line with forecasts. Operating margin fell to 25.2% from 37.8% a year earlier as AI-related costs rose. Billings grew 9.5% to $165.7 million. The company expects next-quarter revenue of about $195.5 million. It raised its full-year revenue guidance midpoint to $680.5 million from $676 million. Active workflow prescribers rose 34%, and 16 of the top 20 pharmaceutical companies bought AI Search programs. Management expects most AI Search revenue to come in the second half of next year. Shares trade at $29.50, down from $33.18 before the results.

Doximity (NYSE:DOCS) shares gap down - Here's why. November 6, 2026 Key points. * Doximity shares fell sharply, opening at $30.26 versus the prior close of $33.18, despite reporting fiscal Q2 revenue and EPS above expectations. * The company raised its FY2027 revenue outlook to $678 million-$683 million and forecast Q3 revenue above consensus; modest year-over-year revenue growth and lower EPS than a year ago may have weighed on the stock. * Litigation adds uncertainty: law firms are publicizing a securities class action alleging Doximity misrepresented the Newsfeed's contribution to growth. The allegations have not been established in court. * Interested in Doximity? Here are five stocks we like better. Doximity, Inc. (NYSE:DOCS - Get Free Report)'s share price gapped down before the market opened on Friday. The stock had previously closed at $33.18, but opened at $30.26. Doximity shares last traded at $30.8450, with a volume of 1,008,882 shares changing hands. Doximity news roundup. Here are the key news stories impacting Doximity this week: * Fiscal Q2 revenue was $174.5 million, ahead of FactSet's $170.8 million estimate, while earnings of $0.36 per share also topped consensus. Revenue grew 3.6% year over year. * Doximity forecast fiscal Q3 revenue of $195 million-$196 million, above the $193.4 million consensus, and lifted its FY2027 revenue outlook to $678 million-$683 million, versus $675.6 million expected. The CEO also cited a 51% adjusted EBITDA margin and AI products purchased by more than 190 health systems. * Needham reaffirmed its "buy" rating and $41 price target, signaling continued analyst confidence. * Despite beating estimates and raising guidance, DOCS shares declined following the results. Revenue growth was modest, and EPS was down from $0.45 in the year-earlier quarter, which may help explain the muted reaction. * Multiple law firms are publicizing a securities class action and the November 16 lead-plaintiff deadline. The suit alleges Doximity misrepresented the Newsfeed's contribution to growth; these claims have not been established in court, but the litigation adds uncertainty. Analyst upgrades and downgrades. A number of equities research analysts recently commented on the company. Raymond James Financial reiterated an "outperform" rating and issued a $38.00 target price on shares of Doximity in a research report on Friday, October 16th. Truist Financial raised their price target on Doximity from $19.00 to $24.00 and gave the company a "hold" rating in a report on Thursday, August 13th. Weiss Ratings raised Doximity from a "hold (c-)" rating to a "hold (c)" rating in a research note on Tuesday, October 6th. Needham & Company LLC reaffirmed a "buy" rating and issued a $41.00 price objective on shares of Doximity in a research note on Friday. Finally, Freedom Capital cut Doximity from a "strong-buy" rating to a "hold" rating in a report on Tuesday, September 8th. Eight research analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of "Hold" and an average target price of $30.73. Discover more MarketBeat All Access MarketBeat Portfolio Tracker MarketBeat Research Tools Doximity stock performance. The stock has a market cap of $5.67 billion, a PE ratio of 37.48, a PEG ratio of 27.12 and a beta of 1.29. The stock has a fifty day moving average price of $28.95 and a 200 day moving average price of $25.55. Doximity (NYSE:DOCS - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.29 earnings per share for the quarter, beating the consensus estimate of $0.16 by $0.13. The company had revenue of $156.62 million for the quarter. Doximity had a return on equity of 18.06% and a net margin of 25.48%. The business's quarterly revenue was up 7.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.36 EPS. As a group, equities analysts anticipate that Doximity, Inc. will post 0.74 earnings per share for the current fiscal year. Insider transactions at Doximity. In other news, Director Phoebe Yang sold 1,290 shares of the firm's stock in a transaction dated Wednesday, September 30th. The shares were sold at an average price of $26.71, for a total value of $34,455.90. Following the completion of the sale, the director owned 24,744 shares in the company, valued at approximately $660,912.24. This trade represents a 4.96% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Siddharth Sitaram sold 2,613 shares of Doximity stock in a transaction dated Wednesday, October 14th. The stock was sold at an average price of $30.68, for a total transaction of $80,166.84. Following the transaction, the chief accounting officer directly owned 101,432 shares of the company's stock, valued at approximately $3,111,933.76. This represents a 2.51% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 13,750 shares of company stock worth $386,310. 31.80% of the stock is currently owned by insiders. Institutional inflows and outflows. Several large investors have recently modified their holdings of the business. Jefferies Financial Group Inc. increased its position in shares of Doximity by 526.3% in the 3rd quarter. Jefferies Financial Group Inc. now owns 179,400 shares of the company's stock valued at $5,084,000 after acquiring an additional 150,755 shares during the period. Riverbridge Partners LLC raised its stake in Doximity by 7.9% in the 3rd quarter. Riverbridge Partners LLC now owns 303,539 shares of the company's stock worth $8,602,000 after acquiring an additional 22,320 shares during the last quarter. Lido Advisors LLC acquired a new stake in Doximity during the 3rd quarter worth about $281,000. M&G PLC lifted its position in Doximity by 96.4% during the 3rd quarter. M&G PLC now owns 577,196 shares of the company's stock worth $16,161,000 after acquiring an additional 283,296 shares during the period. Finally, Fulcrum Asset Management LLP lifted its position in Doximity by 17,401.8% during the 3rd quarter. Fulcrum Asset Management LLP now owns 66,857 shares of the company's stock worth $1,773,000 after acquiring an additional 66,475 shares during the period. Hedge funds and other institutional investors own 87.19% of the company's stock. Doximity company profile. Doximity, Inc operates a digital platform designed for medical professionals in the United States. Its network connects physicians, nurse practitioners, physician assistants, pharmacists and other healthcare professionals, providing tools for professional communication, collaboration and career development. The company offers services including secure messaging, telehealth, digital faxing, physician scheduling and professional networking. Doximity also provides medical news and educational content, as well as recruiting and job-search resources for healthcare professionals. Doximity generates additional revenue through digital marketing and engagement solutions for pharmaceutical companies, healthcare organizations and health systems. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Doximity, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Doximity wasn't on the list. While Doximity currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you'll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America. Continue following MarketBeat